



October 22, 2024

PeptiDream Inc
<https://www.peptidream.com/en/>
(Securities Code: 4587 TSE Prime Market)

PeptiDream Announces Upcoming Presentation of CA9-Targeting PD-32766 Program at the Annual Meeting of the Japan Society of Urologic Oncology

KANAGAWA, JAPAN – October 22, 2024 – PeptiDream Inc., a public Kanagawa, Japan-based biopharmaceutical company (President and CEO: Patrick C. Reid, hereinafter “PeptiDream”) (Tokyo: 4587) announced that the company will be presenting some of the preclinical results of its PD-32766 program targeting Carbonic Anhydrase IX (“CA9”) as a potential targeted radiotherapy and radiodiagnostic for clear cell renal cell carcinoma (“ccRCC”) at the 10th Annual Meeting of the Japan Society of Urologic Oncology held on October 26-27, 2024.

CA9 is a cell surface antigen highly expressed in ~95% of ccRCC patients with minimal expression in normal tissues. PeptiDream is currently developing PD-32766 as both a radiotherapeutic and a radiodiagnostic imaging agent for the potential treatment and diagnosis of ccRCC. Preclinical data showing specific accumulation of PD-32766 radiolabeled with either Copper64 (“⁶⁴Cu”) or Lutetium177 (“¹⁷⁷Lu”) into CA9-expressing tumors, in addition to strong tumor regression after treatment with radiolabeled PD-32766 in mouse xenograft models of RCC will be presented.

Information on the presentation is as follows;

The 10th Annual Meeting of the Japan Society of Urologic Oncology (October 26-27, 2024)

Location: Fukuoka, Fukuoka Prefecture

Title: PD-32766, a CA-9-binding peptide, as potential radiotheranostic agent for renal cell carcinoma.

Presentation Format: Poster Session (MP06-4)

Date: 2:10-3:05pm October 27, 2024 (JT)

About PeptiDream Inc.

PeptiDream Inc. (Tokyo Stock Exchange Prime Market 4587) is leading the translation of macrocyclic peptides into a whole new class of innovative medicines to address unmet medical needs and improve the quality of life of patients worldwide. In its radiopharmaceutical business, through its wholly-owned subsidiary PDRadiopharma, PeptiDream markets and sells a number of approved radiopharmaceuticals and radiodiagnostics in Japan, as well as leveraging its proprietary Peptide Discovery

Platform System (PDPS) technology to discover and develop a deep pipeline of innovative targeted radiotherapeutics and radiodiagnostics, spanning both wholly-owned internal programs and globally partnered programs. In its non-radiopharmaceutical business, PeptiDream is similarly leveraging PDPS to discover and develop a broad and diverse pipeline of investigational peptide therapeutics, peptide drug conjugates (PDC) and multi-functional peptide conjugates (MPC) across an extensive global network of discovery and development partners. PeptiDream is headquartered in Kawasaki, Japan. For more information about our company, science and pipeline, please visit www.peptidream.com/en

Inquiries:

PeptiDream Inc.

Contact: Yuko Okimoto, IR & Public Affairs

Email: info@peptidream.com